Core--Protocol Specific Research Support

方案特定研究支持（PSRS）旨在扩大KCI的药物启动临床试验数量。必须为开展初步研究提供支持，其中大多数研究目前没有得到国家癌症研究所或其他机构的资助。PSRS的目的是提供一个行政支持机制，以提供数据管理，收集患者数据，并支持癌症中心内的创新临床试验。我们的目标是促进由制药商发起的试验，将我们的基础科学实验室的新成果带到临床和人口研究领域。根据科学领导理事会的建议，向研究者授予PSRS。助理中心主任、项目负责人或多学科团队负责人可以提名方案以获得支持。建议评估其科学价值和重要性，在癌症中心内开发新的研究途径。虽然所有建议都得到认真考虑，但鼓励开展研究，表明有可能开发新的研究途径并获得外部资金。在癌症中心内有许多由翻译机构发起的翻译研究。这些包括新的分子靶向治疗和功能成像技术。这些试验试图测试新的靶向治疗，既作为单一药物， 并与更成熟的细胞毒性疗法联合使用。它们通常包括基于血液样本和肿瘤活检的治疗效果测量。新的成像方法是这项工作的组成部分，因为它们提供了一种非侵入性的方法来测试这些治疗方法。 未来，我们计划支持I期、II期和成像/相关试验的混合。 要求为1.5 FTE数据管理提供资金支持，以支持创新试验。数据管理将包括在试验登记前确认患者资格，从各种来源提取和整理数据，确保进行质量控制检查。

The Protocol-Specific Research Support (PSRS) is an effort to expand the number of investigator-initiated clinical trials at KCI. Support must be available to conduct preliminary studies, most of which are not presently funded by the NCI or other agencies. The purpose of the PSRS is to provide an administrative support mechanism to provide data management, collection of patient data, and to support innovative clinical trials within the Cancer Center. The objective is to foster investigator-initiated trials, which bring new results from our basic science laboratories to the clinical and population studies arenas. The awarding of PSRS to an investigator is done at the recommendation of the Scientific Leadersip Council. Associate center directors, Program leaders, or heads of the Multidisciplinary Teams can nominate protocols for support. Proposals are evaluated for their scientific merit and importance in developing new avenues of research within the Cancer Center. Although all proposals are given serious consideration, studies that show the potential to develop new avenues of research and secure external funding are encouraged. There are many investigator-initiated translational studies within the Cancer Center. These include novel and molecular targeted therapies, and functioning imaging techniques. These trials seek to test new, targeted therapies both as single agents, and in combination with more established cytotoxic therapy. They often include measurements of treatment effect based on blood samples and tumor biopsies. New imaging approaches are integral to this work as they provide a noninvasive way to test these treatment approaches. For the future, we plan to support a mixture of Phase I, Phase II, and imaging/correlative trials. Funding support for 1.5 FTE data management to support the innovative trials is requested. Data management will include confirming patient eligibility prior to registration to the trial, abstracting and collating data from various sources ensuring that qualtiy control checks are being conducted.